Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 27, 2026, 12:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 151 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Type Two Diabetes Mellitus Clear all
Recruiting Phase 3 Interventional

A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight

NCT07564414
View directory record Official record
Conditions
Obesity, Type 2 Diabetes
Interventions
Cagrisema, Semaglutide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
99
States / cities
Birmingham, Alabama • Pelham, Alabama • Gilbert, Arizona + 81 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Jun 27, 2026, 12:59 AM EDT
Completed Phase 3 Interventional Results available

A Research Study to Compare Two Semaglutide Medicines in People With Type 2 Diabetes

NCT05478252
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Semaglutide J, Semaglutide B
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 64 Years
Enrollment
388 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
55
States / cities
Gilbert, Arizona • Costa Mesa, California • La Mesa, California + 45 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Jun 27, 2026, 12:59 AM EDT
Completed No phase listed Observational

Computer-based Screening for Diabetic Retinopathy

NCT01614327
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Not listed
Lead sponsor
VisionQuest Biomedical LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
19,199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
2
States / cities
Albuquerque, New Mexico • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 17, 2017 · Synced Jun 27, 2026, 12:59 AM EDT
Completed Phase 1 Interventional Results available

Pancreatic Islet Cell Transplantation

NCT00214786
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Islet cell transplantation
Biological
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 13, 2017 · Synced Jun 27, 2026, 12:59 AM EDT
Completed Not applicable Interventional Results available

Recombinant Human Leptin Therapy Effects on Insulin Action

NCT01207934
View directory record Official record
Conditions
Type Two Diabetes Mellitus
Interventions
placebo, low-dose leptin, high-dose leptin
Dietary Supplement · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
25 Years to 75 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2000
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 8, 2015 · Synced Jun 27, 2026, 12:59 AM EDT
Active, not recruiting Phase 4 Interventional

A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes

NCT05433584
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Tirzepatide, Antihyperglycemic medication
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
780 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
32
States / cities
Birmingham, Alabama • Canoga Park, California • Huntington Park, California + 29 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Jun 27, 2026, 12:59 AM EDT
Completed Not applicable Interventional

Wine Consumption and Glycemic Control

NCT02518334
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Alcohol consumption
Other
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
21 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 25, 2017 · Synced Jun 27, 2026, 12:59 AM EDT
Not listed Not applicable Interventional

A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine

NCT03073343
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease, Non Insulin Dependent Diabetes, ALT
Interventions
Betaine (trimethyglycine)
Dietary Supplement
Lead sponsor
Southern California Institute for Research and Education
Other
Eligibility
18 Years to 75 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2025
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated May 6, 2024 · Synced Jun 27, 2026, 12:59 AM EDT
Completed Not applicable Interventional Results available

Two Way Crossover Closed Loop Study MPC vs FMPD

NCT04771403
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
FMPD AP algorithm, MPC AP system, Dexcom G6 Continuous Glucose Monitoring (CGM) System
Device
Lead sponsor
Oregon Health and Science University
Other
Eligibility
21 Years to 50 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 16, 2023 · Synced Jun 27, 2026, 12:59 AM EDT
Completed Not applicable Interventional

Glycemic Response to Two Enteral Formulas in Persons With Type 2 Diabetes Mellitus

NCT02898766
View directory record Official record
Conditions
Diabetes
Interventions
Enteral Nutrition Formula
Other
Lead sponsor
Société des Produits Nestlé (SPN)
Industry
Eligibility
20 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Tustin, California
Source: ClinicalTrials.gov public record
Updated Oct 10, 2016 · Synced Jun 27, 2026, 12:59 AM EDT
Completed Phase 3 Interventional Results available

A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) in Subjects With Type 2 Diabetes Mellitus Using Two Different Titration Algorithms

NCT02298192
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin degludec/liraglutide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
40
States / cities
Hamilton, Alabama • Chandler, Arizona • Glendale, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated May 22, 2017 · Synced Jun 27, 2026, 12:59 AM EDT
Completed No phase listed Observational

Accuracy Comparison of Two CGMs in Hospitalized Patients

NCT05081817
View directory record Official record
Conditions
Type 1 Diabetes, Type 2 Diabetes
Interventions
Not listed
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jul 31, 2023 · Synced Jun 27, 2026, 12:59 AM EDT
Completed Phase 2 Interventional Results available

A Placebo Controlled Safety and Efficacy Study of MSDC-0160 in Type 2 Diabetes With Active Comparator

NCT00760578
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Placebo, Pioglitazone, MSDC-0160 90 mg, MSDC-0160 220 mg
Drug
Lead sponsor
Metabolic Solutions Development Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
8
States / cities
Los Angeles, California • Miami Gardens, Florida • West Palm Beach, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated May 2, 2013 · Synced Jun 27, 2026, 12:59 AM EDT
Completed Phase 1 Interventional Results available

Effect of a Fixed Pramlintide: Insulin Dose Ratio on Postprandial Glucose in Type 1 Diabetes Mellitus

NCT02500979
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Pramlintide acetate, Placebo, Lispro insulin U-100, Regular insulin U-100
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Chula Vista, California • Portland, Oregon • Chattanooga, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 1, 2018 · Synced Jun 27, 2026, 12:59 AM EDT
Completed Phase 2 Interventional Results available

Sensor-Augmented Insulin Delivery: Insulin Plus Glucagon Versus Insulin Alone

NCT00797823
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Insulin, Asp(B28)-, Glucagon, Placebo
Drug
Lead sponsor
Legacy Health System
Other
Eligibility
21 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 6, 2011 · Synced Jun 27, 2026, 12:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug to Drug Interaction Study of Sotagliflozin With Hydrochlorothiazide

NCT03387657
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Sotagliflozin (SAR439954), Hydrochlorothiazide
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 24, 2022 · Synced Jun 27, 2026, 12:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

To Evaluate the Hormonal Response to Low Blood Sugar After a Single Oral Dose of AZD1656 Suspension

NCT00790153
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Insulin, AZD1656
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
20 Years to 45 Years · Male only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Apr 9, 2009 · Synced Jun 27, 2026, 12:59 AM EDT
Completed Phase 3 Interventional Results available

A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Glargine, in People With Type 2 Diabetes Who Have Not Used Insulin Before

NCT04460885
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin icodec, Insulin glargine
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
984 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
97
States / cities
Birmingham, Alabama • Guntersville, Alabama • Little Rock, Arkansas + 85 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Jun 27, 2026, 12:59 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Exposure to Type II Diabetes for Two Siblings With the Same Parents

NCT01275235
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Not listed
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
20 Years to 34 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Apr 4, 2016 · Synced Jun 27, 2026, 12:59 AM EDT
Completed Phase 2 Interventional Results available

Comparison of Two NN1250 Formulations Versus Insulin Glargine, All in Combination With Metformin in Subjects With Type 2 Diabetes

NCT00611884
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin glargine, insulin degludec, metformin
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
18
States / cities
Inglewood, California • Los Angeles, California • Redlands, California + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2017 · Synced Jun 27, 2026, 12:59 AM EDT
Completed Phase 4 Interventional

Study to Estimate the Effects of Inhaled Versus Intravenous (IV) Infusion of Human Insulin in Subjects With Type 1 Diabetes

NCT00315952
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Exubera
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 50 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 17, 2008 · Synced Jun 27, 2026, 12:59 AM EDT
Completed Phase 3 Interventional Results available

Mylan Insulin Glargine Study

NCT03376789
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
MYL-1501D product using manufacture process V, MYL-1501D product using manufacture process VI
Drug
Lead sponsor
Mylan Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
38
States / cities
Fresno, California • Greenbrae, California • Huntington Beach, California + 33 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Jun 27, 2026, 12:59 AM EDT
Recruiting Not applicable Interventional

Nested Pilot Study Comparing Two Treatments to Reduce Type 2 Diabetes Risk in At-Risk Delawareans

NCT07450118
View directory record Official record
Conditions
Prediabetes
Interventions
National Diabetes Prevention Program (DPP), Sleep Health Digital Application, Time-Restricted Eating (TRE)
Behavioral
Lead sponsor
University of Delaware
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Jun 27, 2026, 12:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence Study of Two Albiglutide Drug Products in Healthy Adult Subjects

NCT02660736
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Albiglutide Liquid Auto-injector, Albiglutide Lyophilized DCC Pen Injector, Placebo Liquid Auto-injector, Placebo Lyophilized DCC Pen injector
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 8, 2016 · Synced Jun 27, 2026, 12:59 AM EDT